Traditional Chinese medicine composition for treating gastrointestinal diseases as well as preparation method and application of traditional Chinese medicine composition

Abstract

The invention discloses a traditional Chinese medicine composition for treating intestinal tract diseases, which is prepared from the following traditional Chinese medicines in parts by weight: 8-15 parts of selfheal, 20-40 parts of nacre mother of pearl, 5-10 parts of radix bupleuri, 3-8 parts of fried fructus aurantii, 3-8 parts of rhizoma cyperi, 6-12 parts of inula flower and 5-9 parts of pericarpium citri reticulatae. The traditional Chinese medicine composition can be used for pertinently treating liver and gall stagnated heat, stomach qi reversal type bile reflux gastritis or gastroesophageal reflux disease, has the specific treatment effects of relieving inflammation, inhibiting local tissue angiogenesis and preventing precancerous lesions and / or canceration, and has good clinical significance.

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical technology, and in particular to a traditional Chinese medicine composition for treating gastrointestinal diseases, its preparation method, and its uses. Background Technology

[0002] Bile is a digestive fluid secreted by hepatocytes within the bile ducts. It is an isotonic solution, and its main components include bile salts, bile acids, bilirubin, reduced glutathione and its conjugates, and oxidized glutathione. During digestion, large amounts of bile are released from the liver and gallbladder into the duodenum, emulsifying fats into droplets to facilitate digestion; it also promotes the absorption of fatty acids and fat-soluble vitamins. Under physiological conditions, bile does not reflux into the stomach or esophagus, nor does it damage the intestines. Under pathological conditions, bile can reflux into the stomach and even the esophagus, damaging the gastric and esophageal mucosa. In some cases, bile can even damage the intestinal mucosa.

[0003] Bile reflux gastritis (BRG) is an inflammation caused by the reflux of bile-rich duodenal contents into the stomach, damaging the gastric mucosal barrier and participating in pathological processes such as gastric mucosal atrophy, intestinal metaplasia, and dysplasia. Clinically, it is characterized by stomach pain, acid reflux, bitter taste in the mouth, nausea, and vomiting. Endoscopic findings include yellow-green mucus in the gastric fundus, a yellowish tinge to the gastric wall due to bile contamination, and active inflammatory changes in the gastric mucosa, manifested as edema, erosion, and congestion. BRG is commonly seen after cholelithiasis, pyloric sphincter dysfunction, cholecystectomy, partial gastrectomy, and gastrointestinal anastomosis. Bile reflux is considered an important pathogenic factor for precancerous lesions and gastric cancer.

[0004] Gastroesophageal reflux disease (GRED) is an inflammatory condition of the esophagus caused by the reflux of gastric and duodenal contents into the esophagus. Its main clinical manifestations include retrosternal burning pain, heartburn, acid reflux, and rib pain. Endoscopic findings include esophageal erosion or ulcers. It severely impacts patients' normal work and life, and in severe cases, can lead to complications such as upper gastrointestinal bleeding and esophageal stricture. Alkaline reflux, primarily bile-based, is one of the main types of GRED. Bile reflux can directly damage esophageal cell membranes and tight junctions, impairing the mucosal barrier and potentially leading to Barrett's esophagus and esophageal adenocarcinoma. Currently, there is no clearly effective treatment for gastrointestinal diseases caused by bile reflux. First-line Western medicines, mainly acid-suppressing drugs, cannot relieve or prevent the symptoms and long-term complications caused by bile reflux.

[0005] Therefore, obtaining a drug that can treat gastrointestinal diseases, namely bile reflux gastritis and gastroesophageal reflux disease, is a technical problem that urgently needs to be solved in this field. Summary of the Invention

[0006] In order to overcome the shortcomings of the prior art, the present invention provides a traditional Chinese medicine composition for treating gastrointestinal diseases, its preparation method and uses, specifically, a drug for treating bile reflux gastritis and esophagitis.

[0007] The first aspect of the present invention provides a traditional Chinese medicine composition for treating gastrointestinal diseases, which is made of the following traditional Chinese medicines in parts by weight: 8-15 parts of Prunella vulgaris, 20-40 parts of pearl powder, 5-10 parts of Bupleurum chinense, 3-8 parts of stir-fried Citrus aurantium, 3-8 parts of Cyperus rotundus, 6-12 parts of Inula japonica and 5-9 parts of Citrus reticulata. Furthermore, the traditional Chinese medicine composition is made from the following traditional Chinese medicines in parts by weight: 9 parts of Prunella vulgaris, 30 parts of pearl powder, 6 parts of Bupleurum chinense, 5 parts of stir-fried Citrus aurantium, 5 parts of Cyperus rotundus, 9 parts of Inula japonica, and 6 parts of Citrus reticulata peel. Furthermore, the gastrointestinal disease is bile reflux gastritis or gastroesophageal reflux disease; The second aspect of the present invention provides a method for preparing any of the above-mentioned traditional Chinese medicine compositions, comprising the following steps: weighing each part of the medicine according to the above-mentioned weight ratio, then adding 3 to 6 times the weight of the traditional Chinese medicine with water, decocting 1 to 3 times, combining the decoctions and concentrating them to 1 / 3 to 1 / 2 of the weight of the added water, thereby obtaining the medicine composition. Furthermore, the mother-of-pearl is first decocted; Furthermore, the Inula japonica is wrapped and decocted; A third aspect of the present invention provides a medicament for treating gastrointestinal diseases, comprising any of the above-mentioned traditional Chinese medicine compositions and a pharmaceutically acceptable carrier; Furthermore, the drug is an oral preparation; The fourth aspect of the present invention provides the use of any of the above-mentioned traditional Chinese medicine compositions or drugs for treating gastrointestinal diseases in the preparation of drugs for treating bile reflux gastritis or gastroesophageal reflux disease; further, the therapeutic effect is to reduce inflammation, inhibit local tissue angiogenesis, and prevent precancerous lesions and / or carcinogenesis; Furthermore, the bile reflux gastritis or gastroesophageal reflux disease is a type of bile reflux gastritis or gastroesophageal reflux disease characterized by liver and gallbladder stagnation and upward flow of stomach qi.

[0008] Beneficial effects Compared with the prior art, the beneficial effects of the present invention are as follows: Traditional Chinese medicine (TCM) attributes bile reflux gastrointestinal disorders to liver qi stagnation and gallbladder heat invading the stomach, leading to an imbalance of yin and yang and disordered qi flow. Over time, this results in the accumulation of pathological products such as phlegm and blood stasis, further deteriorating the digestive tract mucosa. TCM treats gastrointestinal diseases caused by bile reflux by addressing the liver, using a combination of methods to soothe the liver, clear the liver, and calm the liver, thus promoting the smooth flow of liver and stomach qi and harmonizing yin and yang in the body, achieving good clinical efficacy.

[0009] Prunella vulgaris L., the dried spike of Prunella vulgaris L. of the family Lamiaceae. Prunella vulgaris L. is pungent, bitter and cold in nature, and belongs to the liver and gallbladder meridians. It has the effects of clearing the liver and purging fire, improving eyesight, and dissipating nodules and swelling. As a Chinese medicinal material with both medicinal and edible uses, Prunella vulgaris L. has a wide range of market applications and significant economic value. It is the key herb for clearing liver fire and dissipating stasis.

[0010] Concha Margaritifera Usta, the shell of Hyriopsis cumingii (Lea) of the family Unionidae, Cristaria plicata (Leach) or Pteria martensii (Dunker) of the family Pteriidae. It is salty and cold in taste, and belongs to the liver and heart meridians. It can soothe the liver and subdue yang, calm the mind and tranquilize the spirit, and regulate acidity and protect the membrane. The combination of these two herbs serves as the sovereign herb.

[0011] Flos Inulae, the dried capitulum of Inula japonica Thunb. or Inula britannica L. of the family Asteraceae. It is pungent, bitter and salty in taste, and slightly warm in nature. It belongs to the lung, spleen, stomach and large intestine meridians. It can lower qi and resolve phlegm, and arrest vomiting caused by adverse rising of qi. It is a specific herb for treating adverse rising of stomach qi. Lowering stomach qi: Strongly lower adverse qi, targeting symptoms such as reflux, belching and hiccups; Resolving phlegm and fluid-retention: Its saltiness can soften hardness, and can resolve the phlegm and qi stagnation in the esophagus;协同珍珠母:二者一重一轻,一镇一降,构成降逆核心,为本方臣药。(这里原文表述不太准确,推测是想说协同珍珠母,二者一重镇一轻降,构成降逆核心,为本方臣药,翻译为) Collaborating with Concha Margaritifera Usta: One is heavy and the other is light, one is for calming and the other is for descending, forming the core of reversing adverse qi, and serving as the ministerial herb in this formula.

[0012] Radix Bupleuri, the dried root of Bupleurum chinense DC. or Bupleurum scorzonerifolium Willd. of the family Umbelliferae. Bupleuri is a commonly used diaphoretic. Its aliases include Dixun, Shancai, Gucao, Chaicao. It is bitter and slightly cold in nature, and belongs to the liver and gallbladder meridians. It is an important herb for soothing the liver, and has the functions of dredging the qi mechanism of the liver and gallbladder, and guiding various herbs into the liver and gallbladder meridians.

[0013] Fructus Aurantii Immaturus Praeparatus, Fructus Aurantii Immaturus is the dried immature fruit of Citrus aurantium L. of the family Rutaceae and its cultivated varieties. It is bitter, pungent and sour in taste, and warm in nature. It belongs to the spleen and stomach meridians. Functions and indications: Regulate qi and relieve distension, promote qi movement and eliminate fullness. It is used for qi stagnation in the chest and hypochondrium, distending pain, indigestion, phlegm-fluid retention; gastroptosis, rectal prolapse, uterine prolapse.

[0014] Rhizoma Cyperi, the dried rhizome of Cyperus rotundus L. of the family Cyperaceae. It is collected in autumn, the hairs and beards are singed off, and then it is slightly boiled or steamed thoroughly in boiling water and then dried in the sun, or directly dried after singeing. It is used for stagnation of liver qi, chest and hypochondrium distending pain, testicular pain, breast distending pain, qi stagnation in the spleen and stomach, abdominal fullness and stuffiness, distending pain, irregular menstruation, amenorrhea and dysmenorrhea. Collaborating with Radix Bupleuri and Fructus Aurantii Immaturus Praeparatus to soothe the liver and regulate qi, and fundamentally solve the problems of diseases from the aspect of qi mechanism.

[0015] Pericarpium Citri Reticulatae, the dried mature pericarp of Citrus reticulata Blanco of the family Rutaceae and its cultivated varieties. The medicinal materials are divided into "Pericarpium Citri Reticulatae" and "Pericarpium Citri Reticulatae Guangdongense". The mature fruits are picked, the pericarp is peeled off, and then dried in the sun or dried at low temperature. It can not only assist Fructus Aurantii Immaturus Praeparatus and Rhizoma Cyperi in regulating qi and harmonizing the stomach, but also dry dampness and resolve phlegm, and assist Flos Inulae in resolving phlegm turbidity; its warm nature can also assist in restricting the cold nature of Prunella vulgaris L. and Concha Margaritifera Usta This invention has the following technical effects: ① Primarily clearing and descending, combined with clearing and dredging: Prunella vulgaris clears liver fire and treats its heat; pearl powder calms rebellious qi and treats its upward rushing; Inula japonica descends stomach qi and treats its reflux. The three constitute a "clearing-calming-descending" treatment combination. ② Soothing the liver is essential for smooth qi flow: Bupleurum chinense, Citrus aurantium, Cyperus rotundus, and Citrus reticulata are four qi-regulating herbs that regulate qi flow from multiple levels, including soothing the liver, regulating the spleen, and harmonizing the stomach, thus addressing the root cause. ③ Combining cold and warm properties, balancing strength and gentleness: Prunella vulgaris and pearl powder are cold in nature, Inula japonica is slightly warm, and Citrus reticulata is warm, ensuring that the entire formula clears heat without harming the stomach and descends rebellious qi without causing stagnation. ④ Addressing both the symptoms and the root cause, highlighting the key points: Clearing the liver and descending rebellious qi treats the acute symptoms (reflux symptoms), while soothing the liver and regulating qi treats the root cause (liver and gallbladder stagnation). Indications (Liver and Gallbladder Stagnation with Heat, Stomach Qi Rising): Main symptoms: heartburn, acid reflux, bitter taste in the mouth, burning pain or discomfort behind the sternum; Accompanying symptoms: hypochondriac pain, irritability, frequent belching, foreign body sensation in the throat, insomnia and dreaminess; Tongue and pulse characteristics: red tongue, yellow or yellow-greasy coating, wiry or wiry-rapid pulse; Gastroscopy findings: congestion, edema, and erosion of the gastric and / or esophageal mucosa, with bile reflux visible.

[0016] In summary, the present invention has the effect of treating bile reflux gastritis or gastroesophageal reflux disease, specifically by reducing inflammation, inhibiting local tissue angiogenesis, and preventing precancerous lesions and / or carcinogenesis; more specifically, the bile reflux gastritis or gastroesophageal reflux disease is a type of bile reflux gastritis or gastroesophageal reflux disease characterized by liver and gallbladder stagnation and upward flow of stomach qi. Attached Figure Description

[0017] Figure 1 Histopathological observation of a rat model of bile reflux gastritis after treatment Figure 2 Histopathological observation of a rat model of bile reflux esophagitis after treatment Figure 3 The levels of peripheral blood inflammatory factors after treatment in a rat model of bile reflux gastritis Figure 4 The levels of peripheral blood inflammatory factors after treatment in a rat model of bile reflux gastritis Figure 5 Levels of peripheral blood inflammatory factors after treatment in a rat model of bile reflux esophagitis Detailed Implementation The invention will now be further described with reference to the accompanying drawings and specific embodiments. It should be noted that, without conflict, the various embodiments or technical features described below can be arbitrarily combined to form new embodiments. Unless otherwise specified, the materials and equipment used in this embodiment are commercially available. The embodiments described below with reference to the accompanying drawings are exemplary and are only used to explain this application, and should not be construed as limiting this application.

[0018] (I) Implementation Examples Example 1 A traditional Chinese medicine composition is made from the following parts by weight of traditional Chinese medicine: 8g of Prunella vulgaris, 20g of pearl powder (decocted first), 5g of Bupleurum chinense, 3g of stir-fried Citrus aurantium, 3g of Cyperus rotundus, 6g of Inula japonica (decocted in a wrap), and 5g of Citrus reticulata. The preparation method of the traditional Chinese medicine composition includes the following steps: weigh each part by weight of the medicine according to the above weight ratio, pulverize it, then add 5 times the weight of the traditional Chinese medicine with water, decoct 3 times, combine the decoctions and concentrate to 1 / 3 to 1 / 2 of the weight of the added water, and the medicine is obtained.

[0019] Example 2 A traditional Chinese medicine composition is made from the following parts by weight of traditional Chinese medicine: 15g of Prunella vulgaris, 40g of pearl powder (decocted first), 10g of Bupleurum chinense, 8g of stir-fried Citrus aurantium, 8g of Cyperus rotundus, 12g of Inula japonica (decocted in a wrap), and 9g of Citrus reticulata. The preparation method of the traditional Chinese medicine composition includes the following steps: weigh each part by weight of the medicine according to the above weight ratio, pulverize it, then add 5 times the weight of the traditional Chinese medicine with water, decoct 3 times, combine the decoctions and concentrate to 1 / 3 to 1 / 2 of the weight of the added water, and the medicine is obtained.

[0020] Example 3 A traditional Chinese medicine composition is made from the following parts by weight of traditional Chinese medicine: 9g of Prunella vulgaris, 30g of pearl powder (decocted first), 6g of Bupleurum chinense, 5g of Citrus aurantium, 5g of Cyperus rotundus, 9g of Inula japonica (decocted in a wrap), and 6g of Citrus reticulata. The preparation method of the traditional Chinese medicine composition includes the following steps: weigh each part by weight of the medicine according to the above weight ratio, pulverize it, then add 5 times the weight of the traditional Chinese medicine with water, decoct 3 times, combine the decoctions and concentrate to 1 / 3 to 1 / 2 of the weight of the added water, and the medicine is obtained.

[0021] (II) Experimental Examples 1. Experimental grouping and drug administration (1) Normal group: No operation is performed.

[0022] (2) Bile reflux gastritis model group (model group 1): 0.25g lecithin, 1.5g pancreatic enzyme and 2.5g sodium taurocholate were completely dissolved in distilled water (100 mL) to make reflux fluid. The bile reflux gastritis model was established by gavage. Mice were given 15mL / kg of reflux fluid on an empty stomach every day for 28 consecutive days.

[0023] (3) Bile reflux esophagitis model group (model group 2): Total gastrectomy + esophagoduodenal anastomosis was performed to form bile reflux, and the model was successful one week after the operation.

[0024] (4) Treatment group + model group 1: The treatment group was administered traditional Chinese medicine by gavage according to Example 1 and Example 3. The dosage of the decoction of traditional Chinese medicine was converted between human and rat dosages. Model 1 was administered traditional Chinese medicine by gavage 7 days after the reflux fluid was administered by gavage, with an interval of 6 hours between the two reflux fluid administrations. The gavage was continued for 21 days.

[0025] (5) Treatment group + model group 2: The treatment group also received gavage as described in Example 3. The rats were gavage starting one week after the operation and continued for 42 days.

[0026] 2. Obtain materials Rats were fasted for 24 hours after the last administration, but had free access to water. After intramuscular injection of cetirizine, blood was collected from the abdominal aorta (approximately 4 ml in an anticoagulant tube). The blood was then rapidly centrifuged, and the supernatant was collected and stored in EP tubes at -80°C for subsequent plasma cytokine detection. Additionally, the extracted gastric antrum and lower esophageal tissues were fixed in 4% paraformaldehyde for 24 hours. After dehydration, paraffin infiltration, and embedding, the tissues were cut into 4 μm thick sections for histopathological observation after staining.

[0027] 3. Observation Indicators ① Histopathological changes of gastric and esophageal mucosa in each group of rats; ② Peripheral blood cytokine levels in each group of rats.

[0028] 4. Statistics The database was established using SPSS 25.0, and the measurement data were expressed as mean ± standard deviation. Describe the data. For comparisons between two groups of normally distributed quantitative data, use... t For comparisons of multiple groups of normally distributed and homogeneous variance quantitative data, one-way ANOVA is used; for skewed or non-homogeneous variance quantitative data, the rank-sum test is used. Categorical data are described as percentages, and the chi-square test is used for percentage comparisons. A p-value < 0.05 is considered statistically significant.

[0029] 5. Results 5.1 Histopathological changes in rats 5.1.1 Bile reflux gastritis model group In the model group rats, numerous neutrophil infiltrations and lymphoid follicle formation were observed in the lamina propria of the gastric antrum mucosa, along with extensive intestinal metaplasia. In Example 1, the treatment group showed scattered lymphocytes and plasma cells in the lamina propria, with a small amount of intestinal metaplasia. In Example 3, the treatment group showed a few scattered lymphocytes and plasma cells in the lamina propria, but no significant intestinal metaplasia was observed (see Example 3). Figure 1 The table shows the histopathological observation of a rat model of bile reflux gastritis after treatment. A represents the normal group; B the model group; C the treatment group of Example 1; and D the treatment group of Example 3. (Observation field x 100).

[0030] 5.1.2 Bile reflux esophagitis model group The model group rats showed significant pathological changes in their esophageal tissue, mainly manifested as esophageal epithelial thickening, elongation of papillary processes, and focal or widespread ulceration. Some rats also exhibited intestinal metaplasia and dysplasia. Compared with the model group, the treatment group rats showed significantly reduced pathological damage to their esophageal tissue, specifically with a relatively intact esophageal epithelial structure, decreased epithelial thickening and inflammatory cell infiltration, reduced ulcer area in the middle and lower esophagus, and no lesions such as intestinal metaplasia or dysplasia (see [link to treatment group]). Figure 2 Table 2 shows the histopathological observation of a rat model of bile reflux esophagitis after treatment. A1 and A2 represent the normal group; B1 and B2 represent the model group; and C1 and C2 represent the treatment group. The observation fields were X100 and X200, respectively. Semi-quantitative analysis of pathological scores was performed according to Table 1. The results in Table 2 show that the model group had significantly higher scores than the normal group in inflammation aspects such as epithelial thickening, increased papillary number, papillary elongation, lamellar thickening of basal cells, and ulceration. P <0.0001, the score in the treatment group was significantly lower than that in the model group ( P <0.0001); the model group had significantly higher scores for precancerous lesions and cancerous changes than the normal group, while the treatment group had significantly lower scores than the model group ( P= 0.0597); the total pathological score of the model group was significantly higher than that of the normal group ( P <0.0001, the score in the treatment group was significantly lower than that in the model group ( P= 0.0484).

[0031] Table 1. Histopathological Scoring Criteria for Lower Esophageal Segment

[0032] Note: Lower esophageal histopathological scoring criteria: the degree of esophageal inflammation is expressed as - +++++ corresponds to 0 A 5-point scoring system is used; precancerous lesions of the esophagus are scored as follows: +++++ corresponds to 0 A score of 25 is used for scoring; esophageal cancer is scored as follows: +++++ corresponds to 0 The score is out of 100.

[0033] Table 2. Total histopathological scores of the lower esophagus in each group of rats ([M(P25, P75)])

[0034] 5.2 Rat peripheral blood cytokine concentrations 5.2.1 Bile reflux gastritis model group Compared with the normal group, the peripheral blood TNF-α level in the model group rats was significantly higher. α IL-6, IL-1 βThe concentration was significantly increased, and the difference was statistically significant; compared with the model group, the peripheral blood TNF-α concentration in the treatment group rats was significantly higher. α IL-6, IL-1 β The concentration decreased significantly, and the difference was statistically significant (see [link]). Figure 3 This indicates the content of peripheral blood inflammatory factors after treatment in a rat model of bile reflux gastritis. ).

[0035] 5.2.2 Bile reflux esophagitis model group Compared with the normal group, the concentrations of VEGF and CXCL1 in the peripheral blood of rats in the model group were significantly increased, and the differences were statistically significant; compared with the model group, the concentrations of VEGF and CXCL1 in the peripheral blood of rats in the treatment group were significantly decreased, and the differences were statistically significant (see...). Figure 4 This indicates the content of peripheral blood chemokines in a rat model of bile reflux esophagitis after treatment; Figure 5 This indicates the content of peripheral blood inflammatory factors after treatment in a rat model of bile reflux esophagitis. ).

[0036] 6. Conclusion The traditional Chinese medicine composition of this invention can prevent and treat gastritis and esophagitis caused by bile reflux. Specifically, it has the effects of reducing inflammation, inhibiting local tissue angiogenesis, and preventing precancerous lesions and carcinogenesis.

[0037] The above embodiments are merely preferred embodiments of the present invention and should not be construed as limiting the scope of protection of the present invention. Any non-substantial changes and substitutions made by those skilled in the art based on the present invention shall fall within the scope of protection claimed by the present invention.

Claims

1. A traditional Chinese medicine composition for treating gastrointestinal diseases, characterized in that, It is made from the following Chinese medicinal herbs in parts by weight: 8-15 parts of Prunella vulgaris, 20-40 parts of pearl powder, 5-10 parts of Bupleurum chinense, 3-8 parts of stir-fried Citrus aurantium, 3-8 parts of Cyperus rotundus, 6-12 parts of Inula japonica, and 5-9 parts of Citrus reticulata peel.

2. The traditional Chinese medicine composition for treating gastrointestinal diseases according to claim 1, characterized in that, The traditional Chinese medicine composition is made from the following traditional Chinese medicines in parts by weight: 9 parts of Prunella vulgaris, 30 parts of pearl powder, 6 parts of Bupleurum chinense, 5 parts of stir-fried Citrus aurantium, 5 parts of Cyperus rotundus, 9 parts of Inula japonica, and 6 parts of Citrus reticulata peel.

3. The traditional Chinese medicine composition for treating gastrointestinal diseases according to claim 1, characterized in that, The gastrointestinal disease mentioned is bile reflux gastritis or gastroesophageal reflux disease.

4. A method for preparing the traditional Chinese medicine composition according to any one of claims 1 to 2, characterized in that, The process includes the following steps: weigh the medicine according to the above weight ratio, crush it, add 3 to 6 times the weight of the Chinese medicine in water, decoct it 1 to 3 times, combine the decoctions and concentrate it to 1 / 3 to 1 / 2 of the weight of the added water, and the medicine is obtained.

5. The method for preparing the traditional Chinese medicine composition according to claim 3, characterized in that, The mother-of-pearl is first decocted.

6. The method for preparing the traditional Chinese medicine composition according to claim 3, characterized in that, The Inula japonica was wrapped and decocted.

7. A medicine for treating gastrointestinal diseases, characterized in that, It includes the traditional Chinese medicine composition according to any one of claims 1 to 2 and a pharmaceutically acceptable carrier.

8. The medicament for treating gastrointestinal diseases according to claim 6, characterized in that, The drug is an oral preparation.

9. The use of a traditional Chinese medicine composition for treating gastrointestinal diseases according to any one of claims 1 to 2 or a drug for treating gastrointestinal diseases according to any one of claims 6 to 7 in the preparation of a drug for treating bile reflux gastritis or gastroesophageal reflux disease; further, the therapeutic effect is to reduce inflammation, inhibit local tissue angiogenesis, and prevent precancerous lesions and / or carcinogenesis.

10. The use according to claim 9, characterized in that, The bile reflux gastritis or gastroesophageal reflux disease mentioned is the type of bile reflux gastritis or gastroesophageal reflux disease characterized by liver and gallbladder stagnation and upward flow of stomach qi.

Images